A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

Inclusion Criteria: 1. Resectable stage IIIA NSCLC, EGFR mutation-negative and ALK rearrangement negative (8th UICC TNM staging); 2. No prior anti-tumor therapy for NSCLC; 3. Age from 18 to 75 years old; 4. Adequate organ function: Hemoglobin ≥9.0g/L; White blood cell count 4.0\~10×109/L; The absolute value of neutrophils (ANC) ≥ 1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST≤2.5 times the upper limit of normal; The international normalized ratio of prothrombin time is ≤1.5 times the upper limit of normal value, and the partial thromboplastin time is within the range of normal value; Creatinine ≤ 1.5 times the upper limit of normal; 5. No chemotherapy, radiotherapy or hormone therapy for malignant tumors, no history of other malignant tumors, excluding patients who have received hormone therapy for prostate cancer and have had DFS for more than 5 years; 6. ECOG 0～1; Exclusion Criteria: 1. Double primary or multiple primary NSCLC; 2. EGFR mutation or ALK mutation was positive 3. patients with psychosis; 4. Pre-existing or coexisting bleeding disorders; 5. Other uncontrollable and inoperable patients; 6. Patients whose previous operations have prevented this operation from being performed; 7. Female patients who are pregnant or breastfeeding; 8. For patients who are allergic to the drugs in the program.